Senior Principal Scientist, Cell Therapy Research, Molecular Immunobiology and Discovery Team at Bristol-Myers Squibb

Seattle, Washington, United States

Apply Now

Not SpecifiedCompensation

Senior (5 to 8 years), Expert & Leadership (9+ years)Experience Level

Full TimeJob Type

UnknownVisa

Biotechnology, Pharmaceuticals, Cell TherapyIndustries

Requirements

Bachelor's Degree with 10+ years of academic and/or industry experience, or Master's Degree with 8+ years of academic and/or industry experience, or Ph.D. or equivalent advanced degree in the Life Sciences with 6+ years of academic and/or industry experience
Experienced molecular biologist and virologist with a strong background in technology development and viral vector engineering
In-depth conceptual and practical understanding of viral vector and cell engineering strategies, and knowledge of key challenges related to transgene delivery in vitro and in vivo
Previous experience in cellular therapy, industry or academic, is preferred
Preferred: Strong expertise in virology, preferably lentivirology, with some experience with other viruses and non-viral delivery methods
Preferred: Strong understanding of the principles of gene regulation, and in optimizing expression and function of transgenic cargoes
Preferred: Extensive experience with delivery of molecular cargoes into human cell lines and primary cells

Responsibilities

Lead a team to develop innovative molecular engineering strategies and viral production methods to improve expression, function, and throughput
Design experiments, organize and analyze results, and communicate progress to the group
Evaluate and prioritize molecular technologies, gene delivery cassettes, and viral platforms, and deliver complete data packages to allow for timely Go/No Go decisions
Collaborate with SMEs, inside and outside the team, to evaluate the functional impact of proposed novel engineering strategies on performance of CAR and eTCR cell products
Work with other team members and team leaders to enable adoption of novel methods and designs in ongoing programs
Lead a matrixed group of Scientist(s) and Research Associate(s), under the direct but limited supervision of management
Understand the context, impact, and timely communication of data

Skills

Molecular Biology

Virology

Lentiviral Engineering

AAV Engineering

Viral Vector Engineering

Gene Delivery

CAR-T

Transduction

Automation

Molecular Design

Bristol-Myers Squibb

Develops and delivers biopharmaceutical medicines

About Bristol-Myers Squibb

Bristol Myers Squibb (BMS) develops and delivers medicines aimed at treating serious diseases, focusing on areas like cancer, autoimmune diseases, and heart conditions. The company conducts extensive research and development to create new drugs, which are sold after receiving regulatory approval. BMS also produces generic drugs, offering affordable alternatives that meet the same quality standards as their branded counterparts. What sets BMS apart from competitors is its dual focus on both innovative and generic medicines, enhancing access to healthcare. The company's goal is to improve patient outcomes while maintaining a commitment to sustainability and corporate responsibility.

New York City, New YorkHeadquarters

1887Year Founded

$33,706.1MTotal Funding

IPOCompany Stage

Biotechnology, HealthcareIndustries

10,001+Employees

Benefits

Flexible Work Hours

Hybrid Work Options

Professional Development Budget

Risks

Increased competition in oncology from emerging biotech firms like ArsenalBio.

BMS's lawsuit over the 340B Drug Pricing Program may lead to regulatory challenges.

Rapid AI and digital tech evolution may pose integration challenges for BMS.

Differentiation

BMS focuses on innovative cancer treatments through collaborations like ArsenalBio for T cell therapies.

The company emphasizes digital health technologies, enhancing clinical trial management and patient engagement.

BMS offers both innovative and generic medicines, increasing affordable healthcare solutions.

Upsides

BMS's partnership with Medidata enhances clinical research processes and patient outcomes.

The collaboration with AI Proteins advances novel miniprotein-based therapeutics, expanding therapeutic modalities.

BMS's global license agreement with BioArctic expands its portfolio in neurodegenerative diseases.

Land your dream remote job 3x faster with AI

Try Jobo Free